Subodh Agrawal, MD
Pain Medicine · Athens, GANPI 1366443640
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (48.2%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 60 manufacturers reported payments, led by AstraZeneca at 26.5% of the total. Reporting peaked in 2019 at $15,859 and has fallen 81.0% since, to $3,017 in 2025. Among pain medicine clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 493 payments — averaging $68.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$9K
- Sanofi-aventis U.S. LLC$7K
- Novo Nordisk$3K
- Eisai Inc.$2K
- Akcea Therapeutics, Inc.$2K
- Regeneron Healthcare Solutions, Inc.$1K
- plus $10K from 54 others
Across 2 payments — averaging $21,123 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$42K
What the payments were for
- Consulting fees$5,58317%
- Speaking & faculty fees$16,19048%
- Travel & lodging$8813%
- Food & beverage$10,64832%
- Education$2911%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PRALUENT$8,282
- FARXIGA$7,579
- Ozempic$2,100
- LENVIMA$1,890
- Attruby$1,108
- GVOKE PFS$223
- AVEIR$193
- ELIQUIS$188
- FFRct$146
- FreeStyle Libre 2$134
- Confirm Rx$122
- SUNOSI$122
- Barostim Neo System$114
How this compares
$33,593 in reported general payments places this provider in the 95th percentile of 203 pain medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AmvuttraVutrisiran Sodium | 15 | $1,842,853 |
| VyndamaxTafamidis | 64 | $1,469,956 |
| JuxtapidLomitapide Mesylate | 12 | $687,428 |
| WainuaEplontersen Sodium | 11 | $473,823 |
| OzempicSemaglutide | 444 | $466,336 |
| VyndaqelTafamidis Meglumine | 21 | $465,852 |
| MounjaroTirzepatide | 310 | $376,822 |
| EliquisApixaban | 276 | $288,677 |
| Xtampza ErOxycodone Myristate | 616 | $214,278 |
| JardianceEmpagliflozin | 167 | $182,347 |
| EntrestoSacubitril/Valsartan | 157 | $161,190 |
| XareltoRivaroxaban | 166 | $156,821 |
| RybelsusSemaglutide | 76 | $115,640 |
| JanuviaSitagliptin Phosphate | 81 | $91,595 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 53 | $60,501 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Vyndaqel, Eliquis | $637 | $2,224,484361 claims |
| Alnylam Pharmaceuticals Inc.Amvuttra | $490 | $1,842,85315 claims |
| Amryt Pharma Holdings LtdJuxtapid | $47 | $687,42812 claims |
| Novo NordiskOzempic, Rybelsus, Wegovy, Novolog | $2,713 | $602,777563 claims |
| AstraZenecaWainua, Farxiga, Brilinta | $8,896 | $553,828109 claims |
| Lilly USA, LLCMounjaro, Trulicity | $30 | $412,007338 claims |
| Collegium Pharmaceutical, Inc.Xtampza Er | $75 | $214,278616 claims |
| Boehringer IngelheimJardiance | $369 | $182,347167 claims |
| NovartisEntresto | $205 | $161,190157 claims |
| Johnson & JohnsonXarelto | $127 | $156,821166 claims |
| MerckJanuvia, Verquvo | $440 | $114,443100 claims |
| GRT US Holding, Inc.Qutenza | $35 | $56,83216 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 203 pain medicine providers in Georgia.
Other pain medicine in Athens
- Rutvij ShahColumbus$86K
- Siddardth UmapathyFort Eisenhower$41K
- Susheel DuaAtlanta$36K
- Jose MathewLawrenceville$27K
- Zhuo SunAugusta$26K
- Maged HamzaGainesville$24K
- Ankur PatelGainesville$21K
- Margaret RisoGainesville$19K
- Steven HanlingAugusta$19K
- Harsh DangariaMarietta$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.